biostudies-literatureUnknown45(16)Kaski JPPfizer AllianceBristol Myers SquibbAmgen CardiovascularBoston ScientificGedeon Richter PlcEli Lilly and CompanySERVIERNovartis Pharma AGEdwardsMSD-Merck & CoAlliance Daiichi Sankyo Europe GmbHBayer AGBoehringer IngelheimAbbott Vascular IntMenarini Int. OpAstraZenecaMSD-Merck &amp; CoViforDaiichi Sankyo Europe GmbHResMedSanofi<h4>Background and aims</h4>Childhood-onset cardiomyopathies are rare and poorly characterized. This study examined the baseline characteristics and 1-year follow-up of children with cardiomyopathy in the first European Cardiomyopathy Registry.<h4>Methods</h4>Prospective data were collected on individuals aged 1-<18 years enrolled in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis long-term registry (June 2014-December 2016).<h4>Results</h4>A total of 633 individuals aged ≤18 years with hypertrophic [HCM; n = 388 (61.3%)], dilated [DCM; n = 206 (32.5%)], restrictive [RCM; n = 28 (4.4%)], and arrhythmogenic right ventricular cardiomyopathy [ARVC; n = 11 (1.7%)] were enrolled by 23 referral centres in 14 countries. Median age at diagnosisEuropean heart journal1443-1454https://www.ebi.ac.uk/biostudies/studies/S-EPMC11448693biostudies-literatureCardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry.PMC11448693Garcia-Pavia PBaban APapachristou PSalazar-Mendiguchia JKavoliuniene AZaklyazminskaya EPetronio ASGorenflo MAsselbergs FWPetronio APZiesenitz VCantero Perez EMCobo-Marcos MViezelis MCorsini ARuschitzka FElliott PESanchez Fernandez PLJames SKayikcioglu MVlagkouli VBoruc ATramonte SRubino MBobbo MGielen SKomissarova SMasarone DAlonso ALopez Cuenca DRamani FJarvinen TBrzezinska-Rajszys GGimeno Blanes JRAnastasakis ATamuleviciute-Prasciene ECharron PHGarcia-Cuenllas LNiyazova SBax JGallego-Delgado MKaski JPZiolkowska LCirillo AGonzalez JDrago FBriceno AGale CPRagni LSammani AGlikson MTavazzi LPalmieri SPazzanese VLopez-Haldon JERoesch EKourelis GLaroche CKotlukova NIlina MFriberg OMostafa SDweck MServos GBonnet DRammos SOjala TDagata BMatskeplishvili SRossello FJPlata BAdlam DErlinge DAjuluchukwu JKolbasova EBravo LZeymer UKappetein APBudaj ANorrish GDiaz-Pelaez ENeglia DJung AChakova NVagenakis GMilandri ARusso MGMeder BRitsatos KRoos-Hesselink JWManito NTorbica AOlusegun-Joseph ADominguez FGray APena Pena MLTendera MWeidinger FPapadopoulos GKaranasios EVillacorta EPihkala JCalabro RVardas PElliott PCaforio ALMarrazzo TPrescott ECarriere CDel Giorno GCastro FJField ECaforio ALPFerrari REsposito ASorli Garcia MBiagini ECaiazza MCharron PBlomstrom-Lundqvist CNedoshivin AGiannakopoulou ASinagra GBlanes JRGVan de Werf FPopescu BAGagliardi CPinto FVahanian AMerlo MHiippala AEORP Paediatric Cardiomyopathy Registry InvestigatorsVan Der Heijden JPietila MSzezepanski IRea AKirkels JHKhraiche DManiadakis NAvila CGravino RVan Laake LArnold RGraziosi MEkure EValente FIung BUhl SDzemeshkevich SWallentin LShaheen SMEmberson JLimongelli GBeleslin BLund LPasquet AASabater Molina MDagres NCapodanno DPlodzien ELancellotti PKrivickiene ADelgado VNagy KVDe Jonge NLudman PParati GPacileo GDanchin NMaggioni APCequier ARusinova VHausleiter JHeyndrickx GChioncel OMunoz Esparza CfalseCardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry.<h4>Background and aims</h4>Childhood-onset cardiomyopathies are rare and poorly characterized. This study examined the baseline characteristics and 1-year follow-up of children with cardiomyopathy in the first European Cardiomyopathy Registry.<h4>Methods</h4>Prospective data were collected on individuals aged 1-<18 years enrolled in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis long-term registry (June 2014-December 2016).<h4>Results</h4>A total of 633 individuals aged ≤18 years with hypertrophic [HCM; n = 388 (61.3%)], dilated [DCM; n = 206 (32.5%)], restrictive [RCM; n = 28 (4.4%)], and arrhythmogenic right ventricular cardiomyopathy [ARVC; n = 11 (1.7%)] were enrolled by 23 referral centres in 14 countries. Median age at diagnosis2024-01-01T00:00:00Z2024 Apr2025-04-19T19:30:29.889Z2025-04-19T19:30:29.889ZS-EPMC114486933842706410.1093/eurheartj/ehae109